Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market
This article was originally published in The Gray Sheet
Executive Summary
While the genetics firm is not wavering in its legal effort to protect its BRCA gene testing dominance, it is diversifying in response to inevitable competition, with a focus on a multigene panel and companion diagnostics.